Advocacy group questions Medanta MD Naresh Trehan’s inclusion in panel on pharma marketing practices
In a representation to the Department of Pharmaceuticals, the group urges the government to replace Medanta chairman with a member free of potential conflicts of interest.
An advocacy group has questioned the inclusion of Medanta MD Naresh Trehan in a panel established to examine pharmaceutical marketing practices. The group has urged the government to replace Trehan with a member free of potential conflicts of interest, arguing that the committee's independence and impartiality must be upheld. Trehan, the chairman and managing director of Medanta, was included in the panel as part of a Supreme Court directive.
The advocacy group contends that Trehan's financial interests and association with the Medanta Group could introduce a conflict of interest, which would undermine the committee's ability to make transparent and impartial recommendations. The group cited instances of overcharging in hospital tariffs and Supreme Court proceedings, emphasizing the need for ethical practices and access to affordable healthcare.
Written by urgent.news from The Hindu Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
